## Abstract ## BACKGROUND. Ependymomas account for 2% of all intracranial tumors in adults. Supratentorial ependymomas are less common than their infratentorial counterparts. To the authors' knowledge to date, the predictive values of surgery, histology, and patientβrelated prognostic factors for
β¦ LIBER β¦
Retrospective analysis of clinical profile prognostic factors and outcomes of 19 patients of emphysematous pyelonephritis
β Scribed by Ambar Khaira; Ankur Gupta; Devendra S. Rana; Ashwini Gupta; Anil Bhalla; Dinesh Khullar
- Publisher
- Springer Netherlands
- Year
- 2009
- Tongue
- English
- Weight
- 171 KB
- Volume
- 41
- Category
- Article
- ISSN
- 0301-1623
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Supratentorial ependymomas: Prognostic f
β
Philippe Metellus; Dominique Figarella-Branger; Jacques Guyotat; Marylin Barrie;
π
Article
π
2008
π
John Wiley and Sons
π
English
β 342 KB
π 1 views
Infratentorial ependymomas: prognostic f
β
Jacques Guyotat; Philippe Metellus; Roch Giorgi; Marylin Barrie; Anne Jouvet; Mi
π
Article
π
2009
π
Springer Vienna
π
English
β 329 KB
Multivariate analysis of prognostic fact
β
Christian Carrie; Christine Lasset; Claire Alapetite; Jean-Philippe Maire; Chris
π
Article
π
1994
π
John Wiley and Sons
π
English
β 651 KB
Surgical treatment of patients with unil
β
Parmenion P. Tsitsopoulos; Lovisa Tobieson; Per Enblad; Niklas Marklund
π
Article
π
2011
π
Springer Vienna
π
English
β 186 KB
Surgical treatment of patients with unil
β
Parmenion P. Tsitsopoulos; Lovisa Tobieson; Per Enblad; Niklas Marklund
π
Article
π
2011
π
Springer Vienna
π
English
β 186 KB
Significant clinical benefit of first-li
β
Vasilios Karavasilis; Beatrice M. Seddon; Susan Ashley; Omar Al-Muderis; Cyril F
π
Article
π
2008
π
John Wiley and Sons
π
English
β 105 KB
π 1 views
## Abstract ## BACKGROUND. The efficacy of palliative chemotherapy was investigated in a large group of patients with advanced softβtissue sarcomas (STS) treated on routine palliative protocols. ## METHODS. Patients with STS who had firstβline chemotherapy for advanced and/or metastatic disease